A 32-year-old woman from Mumbai presents with bilateral breast cancer diagnosed 6 months apart. Her mother died of ovarian cancer at age 45, and her maternal grandmother had breast cancer at age 38. Genetic testing reveals a pathogenic BRCA1 mutation. What is the most appropriate next step in management?

Question

Accepted Answer

C. Bilateral mastectomy and bilateral salpingo-oophorectomy after completion of current chemotherapy. ## Clinical Context
This patient has a BRCA1 germline mutation with early-onset bilateral breast cancer and a strong family history of BRCA-associated malignancies (breast and ovarian cancer). BRCA1/2 mutations confer a lifetime risk of ~70% for breast cancer and ~40% for ovarian cancer.

## Management Strategy for BRCA1 Carriers with Established Cancer

**Key Point:** Once a BRCA1 mutation is confirmed in a patient with cancer, the standard of care includes:
1. Completion of cancer treatment (chemotherapy/surgery for current malignancy)
2. Risk-reducing bilateral salpingo-oophorectomy (RRSO) — typically after age 40 or completion of childbearing
3. Risk-reducing bilateral mastectomy (RRM) — offered as an option, especially with bilateral disease

**High-Yield:** RRSO is particularly important because:
- Reduces ovarian cancer risk by ~80%
- Reduces breast cancer risk by ~50% (via estrogen deprivation) if performed premenopausally
- Eliminates need for intensive ovarian cancer surveillance

## Why This Patient Needs Bilateral Procedures

| Procedure | Indication | Risk Reduction |
|-----------|-----------|----------------|
| RRSO | BRCA1+ status + completed childbearing | Ovarian cancer ~80%, breast cancer ~50% |
| RRM | Bilateral breast cancer + BRCA1+ | Contralateral breast cancer risk ~40% lifetime |

**Clinical Pearl:** The sequence is: complete active cancer treatment → offer genetic counseling and discuss options → proceed with risk-reducing surgery. Both procedures are offered, though RRSO is more strongly recommended due to higher ovarian cancer mortality.

**Mnemonic:** BRCA-RRSO = **B**RCA carriers need **R**isk-**R**educing **S**alpingo-**O**ophorectomy (and consider RRM for bilateral disease).

[cite:Robbins 10e Ch 7]

Answer

A. Tamoxifen 20 mg daily for 5 years as chemoprevention

Answer

B. Annual mammography and clinical breast examination only

Answer

D. Observation with supportive care; genetic mutations do not alter prognosis

Explanation

Clinical Context

Management Strategy for BRCA1 Carriers with Established Cancer

Why This Patient Needs Bilateral Procedures

Practice similar questions

Join our NEET PG community

Procedure	Indication	Risk Reduction
RRSO	BRCA1+ status + completed childbearing	Ovarian cancer _{80%, breast cancer}50%
RRM	Bilateral breast cancer + BRCA1+	Contralateral breast cancer risk ~40% lifetime